← Leaderboards
Padma Rajagopal
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTranscriptome SequencingTumorMalignant Breast NeoplasmAlgorithmsVariantTreatment ResponsePredicting ResponseTranscriptomeMetastatic Breast CancerPrecision OncologyClinical TrialsParticipantTriple-Negative Invasive Breast CarcinomaMutationData SetTargeted TreatmentBrca GeneGerm LinesPathogenicityGenesImmunotherapyTranscriptomicsTechnology
Grant awards (19)
Long-Read DNA Sequencing and RNA Sequencing in LFS-Like Families$218,737
ZIA · FY2025 · CA · contact PI
Leveraging RNA and synthetic lethality to predict response to treatment in breast cancer (including BRCA-mutated)$187,489
ZIA · FY2025 · CA · contact PI
Identifying Treatment Options using RNA-Based Synthetic Lethality and Rescue$124,992
ZIA · FY2025 · CA · contact PI
Germline-Somatic Interactions and Association with Treatment Response in Cancer$93,744
ZIA · FY2025 · CA · contact PI
Leveraging RNA and synthetic lethality in germline BRCA-mut breast cancer$183,850
ZIA · FY2024 · CA · contact PI
Identifying Treatment Options using RNA-Based Synthetic Lethality and Rescue$183,850
ZIA · FY2024 · CA · contact PI
Germline-Somatic Interactions and Association with Treatment Response in Cancer$122,567
ZIA · FY2024 · CA · contact PI
Long-Read DNA Sequencing and RNA Sequencing in LFS-Like Families$116,437
ZIA · FY2024 · CA · contact PI
IDENTIFY Study: Natural History of Maternal Neoplasia$6,128
ZIA · FY2024 · CA · contact PI
Identifying Treatment Options using RNA-Based Synthetic Lethality and Rescue$171,390
ZIA · FY2023 · CA · contact PI
Leveraging RNA and synthetic lethality in germline BRCA-mut breast cancer$171,390
ZIA · FY2023 · CA · contact PI
Long-Read DNA Sequencing and RNA Sequencing in LFS-Like Families$114,260
ZIA · FY2023 · CA · contact PI
Germline-Somatic Interactions and Association with Treatment Response in Cancer$85,695
ZIA · FY2023 · CA · contact PI
IDENTIFY Study: Natural History of Maternal Neoplasia$28,565
ZIA · FY2023 · CA · contact PI
Germline-Somatic Interactions and Association with Treatment Response in Cancer$210,792
ZIA · FY2022 · CA · contact PI
Identifying Treatment Options using RNA-Based Synthetic Lethality and Rescue$158,095
ZIA · FY2022 · CA · contact PI
Leveraging RNA and synthetic lethality in germline BRCA-mut breast cancer$158,095
ZIA · FY2022 · CA · contact PI
Identifying germline-somatic and synthetic lethal targets in hereditary cancers$58,521
ZIA · FY2021 · CA · contact PI
Identifying synthetic lethal targets in metastatic triple negative breast cancer$14,630
ZIA · FY2021 · CA · contact PI